Technical Analysis for ATOS - Atossa Genetics Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 2.63% | |
| Up 3 Days in a Row | Strength | 2.63% | |
| Up 4 Days in a Row | Strength | 2.63% | |
| Shooting Star Candlestick | Bearish | 4.00% | |
| Wide Bands | Range Expansion | 4.00% | |
| Up 3 Days in a Row | Strength | 4.00% | |
| Oversold Stochastic | Weakness | 4.00% | |
| 1,2,3 Retracement Bearish | Bearish Swing Setup | 4.70% | |
| Strong but Oversold | Other | 4.70% | |
| Wide Bands | Range Expansion | 4.70% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 2 hours ago |
| Rose Above Previous Day's High | about 4 hours ago |
| Up 3% | about 4 hours ago |
| Up 2% | about 4 hours ago |
| Up 1% | about 4 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/13/2024
Atossa Genetics Inc. Description
Atossa Genetics, Inc. operates as a healthcare company that focuses on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer in the United States. Its diagnostic tests include the ForeCYTE Breast Health Test, which provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65; and the ArgusCYTE Breast Health Test that offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company also intends to offers FullCYTE Breast Health Test, which is in development to assess the individual breast ducts for pre-cancerous changes in women; and NextCYTE Breast Cancer Test that is in the prevalidation phase to profile breast cancer specimens for prediction of treatment outcomes and distant recurrence in women newly diagnosed with breast cancer. Atossa Genetics, Inc. was founded in 2009 and is headquartered in Seattle, Washington.
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Cancer Cancer Treatment Breast Cancer Genetics Diagnostic Tests Risk Assessment Assessment Products Breast Surgery Breast Implant Hereditary Cancers
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.31 |
| 52 Week Low | 0.6 |
| Average Volume | 2,002,695 |
| 200-Day Moving Average | 0.98 |
| 50-Day Moving Average | 1.42 |
| 20-Day Moving Average | 1.69 |
| 10-Day Moving Average | 1.50 |
| Average True Range | 0.18 |
| RSI (14) | 48.45 |
| ADX | 30.09 |
| +DI | 19.17 |
| -DI | 21.31 |
| Chandelier Exit (Long, 3 ATRs) | 1.78 |
| Chandelier Exit (Short, 3 ATRs) | 1.77 |
| Upper Bollinger Bands | 2.13 |
| Lower Bollinger Band | 1.25 |
| Percent B (%b) | 0.31 |
| BandWidth | 52.29 |
| MACD Line | -0.01 |
| MACD Signal Line | 0.03 |
| MACD Histogram | -0.0471 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.70 | ||||
| Resistance 3 (R3) | 1.70 | 1.63 | 1.67 | ||
| Resistance 2 (R2) | 1.63 | 1.59 | 1.64 | 1.66 | |
| Resistance 1 (R1) | 1.58 | 1.56 | 1.61 | 1.58 | 1.65 |
| Pivot Point | 1.51 | 1.51 | 1.53 | 1.52 | 1.51 |
| Support 1 (S1) | 1.46 | 1.47 | 1.49 | 1.46 | 1.39 |
| Support 2 (S2) | 1.39 | 1.44 | 1.40 | 1.38 | |
| Support 3 (S3) | 1.34 | 1.39 | 1.37 | ||
| Support 4 (S4) | 1.34 |
